Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease

• Published in: International journal of cardiology Vol. 150; no. 1; pp. 39 - 44
• Main Authors: Lordkipanidzé, Marie, Pharand, Chantal, Schampaert, Erick, Palisaitis, Donald A, Diodati, Jean G
• Format: Journal Article
• Language: English
• Published: Shannon Elsevier Ireland Ltd 01.07.2011; Elsevier
• Subjects: Adult; Aspirin; Aspirin - pharmacology; Aspirin - therapeutic use; Biological and medical sciences; Cardiology. Vascular system; Cardiovascular; Coronary artery disease; Coronary Artery Disease - drug therapy; Coronary Artery Disease - enzymology; Coronary heart disease; Cyclooxygenase; Cyclooxygenase Inhibitors - pharmacology; Cyclooxygenase Inhibitors - therapeutic use; Female; Genetic Heterogeneity - drug effects; Heart; Humans; Male; Medical sciences; Middle Aged; Platelet aggregation; Platelet Aggregation Inhibitors - pharmacology; Platelet Aggregation Inhibitors - therapeutic use; Prostaglandin-Endoperoxide Synthases - metabolism; Thromboxane; Thromboxane A2 - antagonists & inhibitors; Thromboxane A2 - metabolism; Thromboxane B2 - antagonists & inhibitors; Thromboxane B2 - metabolism; Aspirin; Cyclooxygenase; Platelet aggregation; Thromboxane; Coronary artery disease; Prostaglandin-endoperoxide synthase; Enzyme; Cardiovascular disease; Acetylsalicylic acid; Coronary heart disease; Heterogeneity; Platelet; Oxidoreductases; Inhibition; Cardiology
• ISSN: 0167-5273; 1874-1754
• DOI: 10.1016/j.ijcard.2010.02.025

Abstract Background Platelets, long believed to be incapable of de novo protein synthesis, may retain their ability to form the cyclooxygenase (COX) enzyme once it has been inactivated by aspirin. This may explain the inefficacy of the drug to induce sustained platelet inhibition in certain patients. We evaluated the stability of platelet inhibition following once-daily enteric-coated aspirin administration. Methods Platelet responsiveness to aspirin was evaluated in 11 stable coronary artery disease patients on chronic aspirin therapy before and 1, 3, 8, and 24 h after observed ingestion of 80-mg enteric-coated aspirin. Inhibition of the COX pathway was measured pharmacologically through plasma thromboxane (Tx) B2 levels, and functionally by light transmission aggregometry in response to arachidonic acid. COX-independent platelet activity was measured in response to adenosine diphosphate, epinephrine and collagen. Results Plasma TxB2 levels showed profound inhibition of TxA2 formation, which was stable throughout 24 h, in all but 1 subject. This subject had optimal response to aspirin (inhibition of platelet TxA2 production within 1 h), but recovered the ability to synthesize TxA2 within 24 h of aspirin ingestion. Arachidonic acid-induced platelet aggregation closely mirrored TxB2 formation in this patient, portraying a functional ability of the platelet to aggregate within 24 h of aspirin ingestion. COX-independent platelet aggregation triggered TxA2 production to a similar extent in all patients, likely through signal-dependent protein synthesis. Conclusions COX-dependent platelet activity is recovered in certain individuals within 24 h of aspirin administration. Further research should consider increasing aspirin dosing frequency to twice daily, to allow sustained inhibition in such subjects.